ST. PAUL, Minn., Oct. 16, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), a developer of minimally invasive medical
devices to treat obesity, metabolic diseases and other
gastrointestinal disorders, today announced that the Company and
its products will be the subjects of two oral presentations and one
poster presentation at ObesityWeek 2017, taking place in
Washington, D.C. from October 29, 2017 to November 2, 2017.
The presentations will feature:
- vBloc® Real-World Patient Data
- ReShape® Integrated Dual Balloon
System Patient Data
- Gastric Vest™ System Initial Clinical Results
Details of the presentations are as follows:
Tuesday, October 31, 2017:
2:13PM ET: Poster
Presentation
|
Presentation Title:
|
A5292 Short-Term
Results for Intermittent Vagal Nerve Blocking (vBloc) in the
"Real-World", Non-Research Environment
|
|
|
|
Presenter:
|
Scott Shikora, M.D.,
F.A.C.S., F.A.S.M.B.S., Professor of Surgery at Harvard Medical
School; Director of the Center for Metabolic and Bariatric Surgery
at Brigham and Women's Hospital
|
Thursday, November 2, 2017:
Podium Presentations
|
Location:
|
Maryland A,
Ballroom Level
|
|
|
|
Session:
|
ASMBS PAPER
SESSION V ENDOSCOPY & EMERGING TECHNOLOGY
|
|
|
|
2:14PM
ET
|
|
|
|
|
Presentation Title:
|
A149 Intragastric
Balloon: 342 Patients Treated at a Multicenter Bariatric
Practice
|
|
|
|
Presenters:
|
Shawn Garber, M.D.,
FACS FASMBS, New York Bariatric Group
|
|
|
|
2:36PM
ET
|
|
|
|
|
Presentation Title:
|
A151 Gastric Vest
System: Initial Results of a Novel Restrictive Bariatric
Procedure
|
|
|
|
Presenters:
|
Juan Antonio
Lopez-Corvala, M.D., Professor of Surgery, Medical Faculty of the
Autonomous University of Baja California; Leader in Bariatric
Surgery Program, Hospital Ángeles Tijuana.
|
For more details on ObesityWeek 2017, please visit
https://obesityweek.com.
About EnteroMedics Inc.
EnteroMedics is a medical
device company focused on the development and commercialization of
technology to treat obesity and metabolic diseases. vBloc®
Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like
device called the vBloc System, is designed to help patients feel
full and eat less by intermittently blocking hunger signals on the
vagus nerve. The Company's ReShape® Integrated
Dual Balloon System involves a non-surgical weight loss procedure
that uses advanced balloon technology designed to help people with
a 30-40 Body Mass Index (BMI), and at least one co-morbidity, lose
weight. The ReShape Procedure was approved by the U.S. Food
and Drug Administration in July of 2015 and has been available in
Europe since 2011. The Gastric
Vest™ System (GVS) is an investigational, minimally invasive,
laparoscopically implanted medical device being studied for weight
loss in obese and morbidly obese patients. The device wraps around
the stomach, emulating the effect of conventional weight-loss
surgery, and is intended to enable gastric volume reduction without
permanently changing patient anatomy. EnteroMedics acquired
the Gastric Vest System through its acquisition of BarioSurg, Inc.
in May 2017 and the ReShape
Dual Intragastric Balloon through its acquisition of ReShape
Medical in October 2017.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as expect," "plan," "anticipate," "could,"
"may," "intend," "will," "continue," "future," other words of
similar meaning and the use of future dates. These forward-looking
statements are based on the current expectations of our management
and involve known and unknown risks and uncertainties that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others: our
limited history of operations; our losses since inception and for
the foreseeable future; our limited commercial sales experience
with our vBloc® System for the treatment of obesity in the United States or in any foreign market
other than Australia and the
European Community; the competitive industry in which we operate;
our ability to maintain compliance with the Nasdaq continued
listing requirements; our ability to commercialize our vBloc
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc System; physician adoption of our vBloc
System and vBloc Neurometabolic Therapy; our ability to obtain
third party coding, coverage or payment levels; ongoing regulatory
compliance; our dependence on third party manufacturers and
suppliers; the successful development of our sales and marketing
capabilities; our ability to raise additional capital when needed;
international commercialization and operation; our ability to
attract and retain management and other personnel and to manage our
growth effectively; potential product liability claims; the cost
and management time of operating a public company; potential
healthcare fraud and abuse claims; healthcare legislative reform;
and our ability to obtain and maintain intellectual property
protection for our technology and products. These and additional
risks and uncertainties are described more fully in the Company's
filings with the Securities and Exchange Commission, particularly
those factors identified as "risk factors" in Exhibit 99.3 of our
current report on Form 8-K filed July 26, 2017. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/enteromedics-announces-presentations-at-obesityweek-2017-300536885.html
SOURCE EnteroMedics Inc.